Anthracyclines (ANTs) remain essential in many anticancer regimens, yet their clinical utility is often limited by multidrug resistance. Recent studies suggest that Bruton's tyrosine kinase inhibitors (BTKis) may enhance the efficacy of ANT-based therapies, including those targeting brain tumors. This study investigates how tirabrutinib may contribute to such enhancement via interactions with aldo-keto reductase 1C3 (AKR1C3) and ABC efflux transporters.

Betahistine hydrochloride is critical for Ménière's syndrome treatment. Validating bioequivalence of generic and reference formulations under fasting/postprandial conditions is key for clinical substitution.

Pregnant women are customarily excluded from phase 1 and 2 clinical trials which, respectively, provide the earliest indication of drug safety and efficacy. This leads to lack of pregnancy-specific safety information for over 90% of approved drugs, including many commonly used during the first trimester.

Methotrexate (MTX) is a type of disease-modifying antirheumatic drug and one of the most effective anticancer agents in clinical practices. However, hepatotoxicity and nephrotoxicity are common side effects associated with MTX therapy. Complementary natural medicines for treating hepatorenal toxicity have received widespread research interest.

The prescription of psychotropic drugs during pregnancy is a constantly increasing practice, but its safety information remains limited. On the other side, while concerns about teratogenicity persist, it is also evident that mothers' psychiatric disorders represent a risk factor for both them and the infants and cannot be neglected or left untreated. Therefore, careful monitoring and dose adjustments are essential to minimize risks while ensuring treatment efficacy.

In psychopharmacology there is a growing interest in potential sex differences regarding psychotropic drugs, currently used or under development. Preclinical research repeatedly identifies sex differences in pharmacokinetics and pharmacodynamics of psychotropic drugs. However, clinical research either does not consistently corroborate such findings or does not necessarily support their clinical significance.

The combination of the JAK1/2 inhibitor KL130008 with methotrexate (MTX) is expected to improve treatment outcomes in rheumatoid arthritis (RA). This study evaluated the pharmacokinetics and safety of this combination therapy.

Carbapenem-resistant Acinetobacter baumannii (CRAB) is an urgent-priority pathogen that is associated with high mortality and leaves clinicians reliant on nephrotoxic salvage regimens. Sulbactam/durlobactam (S/D) pairs sulbactam's intrinsic anti-Acinetobacter activity with the broad Ambler class A/C/D β-lactamase inhibitor durlobactam, creating the first agent targeting CRAB.

Short bowel syndrome (SBS) is a malabsorptive condition that may impair drug absorption, including direct oral anticoagulants such as apixaban. This study aimed to assess whether the pharmacokinetics (PK) of apixaban in patients with SBS differs from those observed in individuals with an intact gastrointestinal (GI) tract, using Bayesian re-estimation with an existing population PK (pop PK) model.

Coumarin exhibit various biological activities, including anti-inflammatory, antioxidant and anxiolytic effects. However, its clinical application is restricted due to significant hepatotoxicity observed in multiple animal models. CYP2A5 is the primary enzyme responsible for metabolizing coumarin in the mouse liver, homologous to human CYP2A6.

Dr. Hyman Zimmerman observed that 'hepatocellular jaundice' was a prognostic biomarker of severe drug-induced liver injury (DILI). His sentinel observation eventually became known as 'Hy's Law' which the FDA currently defines as an ALT or AST greater than 3X ULN with a total bilirubin > 2X ULN in the absence of cholestasis (i.e. alkaline phosphatase > 2X ULN) and with no other more plausible cause identified. The modern idiosyncratic DILI era has introduced variables including novel drug classes, abnormal baseline liver labs and cholestatic DILI phenotypes, that pressure-test the universal applicability of the current Hy's Law definition.

This review examines clinically relevant drug interactions (DIs) between newer antidepressants and medications used to manage neurological disorders frequently comorbid with depression, including Parkinson's disease, Alzheimer's disease, migraine, multiple sclerosis, and neuropathic pain.

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infections induce immunological and inflammatory reactions that may have an impact on cytochrome P450 activity, altering the metabolism of psychotropic drugs. In a cohort study, we prospectively investigated whether SARS-CoV-2 vaccination affects plasma levels of psychotropic agents in association with inflammatory parameter changes.

To assess the risk of adverse offspring outcomes related to paternal antiseizure treatment during conception.

Adverse drug reactions may be increased by combining benzodiazepines and drugs related (BZDR) with clozapine. We aimed to synthesize clinically relevant information on the risks and benefits co-prescribing clozapine and BZDR.

Advanced artificial intelligence (AI) frameworks particularly, large language models (LLMs) have recently attracted attention for automating Drug-drug interactions (DDIs) extraction and prediction tasks. However, there is a scarcity of reviews on how LLMs can rapidly identify known and novel DDIs.

Vunakizumab (SHR-1314) is a novel IL-17A monoclonal antibody that has demonstrated great efficacy and safety in treating moderate-to-severe plaque psoriasis. This study aimed to evaluate the pharmacokinetics and safety of vunakizumab to healthy subjects following subcutaneous administration via a single 2 mL automatic injection (AI) pen compared to two 1 mL AI pen injections.